Arix Bioscience was a global venture capital firm focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. It was listed on the London Stock Exchange and sourced, financed, and built healthcare businesses at all stages of development.
57% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (43% of deals). Average disclosed round size is $73.2M (across 18 rounds with reported amounts).
Portfolio
20
Fund Size
$127M
Top Stage
Series B
Last 12 Mo
0
Team
CS
Christian Schetter
Managing Director
JT
Jonathan Tobin
Managing Director
TK
Tassos Konstantinou
Managing Director
TX
Tim Xu
Principal
FB
Felix Breyer
Analyst
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
23 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ensoma | Series B | $135M | May 2023 |
 Evommune | Series B | $50M | Apr 2023 |
 Disc Medicine | Series B | $90M | Sep 2021 |
 Artios Pharma | Series C | $153M | Jul 2021 |
| AAmplyx Pharmaceuticals, Inc. | Series C | — | May 2020 |
 Quench Bio | Series A | $50M | Jan 2020 |
| SStipe Therapeutics | Series A | — | Oct 2019 |
 Artios Pharma | Series B | $84M | Aug 2018 |
| Artios Pharma | Series B | $84M | Aug 2018 |
| Artios Pharma | Series B | — | Jan 2018 |
| AAtox Bio | Unknown | $30M | Dec 2017 |
 Autolus Therapeutics plc | Unknown | $80M | Sep 2017 |
| AAmplyx Pharmaceuticals, Inc. | Series C | $67M | Aug 2017 |
 Amplyx Pharmaceuticals | Series C | $67M | Aug 2017 |
 LogicBio | Series B | $45M | Jun 2017 |
| MMitoconix Bio | Series A | $20M | Jun 2017 |
| VVerona Pharma PLC | Unknown | $44.7M | Jun 2016 |
| AArtios | Series C | — | — |
 Iterum Therapeutics | Series B | $65M | — |
| VVelosBio | Series B | $137M | — |
 Depixus | Series A | — | — |
| AArtios Pharma Limited | Series B | $84M | — |
| SSorriso | Series A | $31M | — |
Top Co-Investors
Sofinnova Partners9 shared
Andera Partners8 shared
Pfizer Ventures7 shared
SV Health Investors6 shared
M Ventures6 shared
OrbiMed6 shared
IP Group plc5 shared
Pappas Capital5 shared
New Enterprise Associates5 shared
RA Capital Management4 shared
Cormorant Asset Management3 shared
AbbVie3 shared
RiverVest Venture Partners3 shared
BioMed Ventures3 shared
EQT Life Sciences2 shared
Avid Ventures2 shared
Novartis Pharma AG2 shared
SymBiosis2 shared
Atlas Venture2 shared
Alexandria Venture Investments2 shared
Last updated: 8 September 2026